| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Hirsutine targets L-type calcium channels, blocking Ca2+ influx and inhibiting intracellular Ca2+ release, which contributes to its vasodilatory and cardiovascular effects. It also targets Flavivirus, specifically Dengue virus, and induces apoptosis in cancer cells. In breast cancer cells, it inhibits HER2, NF-κB, and Akt pathways while activating the p38 MAPK pathway.
|
|---|---|
| ln Vitro |
Hirsutine's IC50 values were 447.79 and 179.06 μM, respectively, indicating a time- and dose-dependent significant reduction in the viability of MCF-7 and MDA-MB-231 cells. Hirsutine releases Cyt C from mitochondria, accelerates caspase 9 and caspase 3, and causes MDA-MB-231 cells to undergo apoptosis and MMP depolarization [2].
In vitro, Hirsutine remarkably reduces the viability of MCF-7 and MDA-MB-231 breast cancer cells in a time- and dose-dependent manner, with IC50 values of 447.79 and 179.06 μM, respectively. In MDA-MB-231 cells, it induces apoptosis, MMP depolarization, Cyt C release from mitochondria, and activates caspase-9 and caspase-3. It shows selective cytotoxicity against HER2-positive/p53-mutated MDA-MB-453 and BT474 cells, while HER2-negative/p53 wild-type MCF-7 and ZR-75-1 cells are resistant. Hirsutine triggers apoptosis via caspase activation and DNA damage response (γH2AX upregulation) in sensitive cells. |
| ln Vivo |
Human lung cancer cells undergo mPTP-dependent apoptosis when exposed to hirsutine via the ROCK1/PTEN/PI3K/GSK3β pathway [3].
In vivo, Hirsutine induces mPTP-dependent apoptosis through the ROCK1/PTEN/PI3K/GSK3β pathway in human lung cancer cells. Its documented pharmacokinetic profile, characterized by low oral bioavailability (~4.4% in rats), provides a defined benchmark for drug delivery and formulation studies. It has been explored for cardiovascular health applications due to its vasodilatory and antiplatelet activities. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Hirsutine involve calcium channel blocking studies using patch-clamp electrophysiology or fluorescent calcium indicators in cell lines expressing L-type calcium channels. Radioligand binding assays can be performed to assess its interaction with calcium channels. Its anti-Dengue virus activity is evaluated using viral replication assays in infected cell cultures.
|
| Cell Assay |
In vitro cellular assays for Hirsutine are performed using various human breast cancer cell lines (MDA-MB-453, BT474, MCF-7, MDA-MB-231) and lung cancer cells. Cells are treated with compound concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining, MMP depolarization, and caspase activity assays. HER2, NF-κB, Akt, and p38 MAPK pathway proteins are analyzed by Western blotting.
|
| Animal Protocol |
In vivo animal studies for Hirsutine are conducted in tumor xenograft models, typically using immunodeficient mice bearing human cancer cell-derived tumors. The compound is administered orally or intraperitoneally. Endpoints include tumor growth inhibition, survival analysis, and mechanistic studies of the ROCK1/PTEN/PI3K/GSK3β pathway. Pharmacokinetic studies in rats involve oral and intravenous administration to determine bioavailability and other PK parameters.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies in rats show that Hirsutine has low oral bioavailability (~4.4%), which serves as a negative control for formulation studies. It is soluble in DMSO (100 mg/mL). The compound has a molecular weight of 368.47 g/mol and a molecular formula of C22H28N2O3. Its half-life and other PK parameters are not extensively detailed in the available literature but are established in formulation research contexts.
|
| Toxicity/Toxicokinetics |
Hirsutine exhibits low toxicity, as indicated by its use in research as a Dengue virus inhibitor with low cytotoxicity. In in vitro studies, it shows selective cytotoxicity against cancer cells while being less toxic to normal cells. No significant acute toxicity has been reported at the concentrations used in research. The compound is designated for research use only and is not intended for human therapeutic applications.
|
| References |
|
| Additional Infomation |
It has been reported that trichomes are present in Uncaria sinensis, Uncaria rhynchophylla, and other organisms with relevant data. See also: Needlesia asiatica (partial).
Hirsutine is an indole alkaloid from Uncaria rhynchophylla that blocks L-type Ca2+ channels and inhibits intracellular Ca2+ release. It has anticancer, cardioprotective, anti-hypertensive, anti-arrhythmic, and vasodilatory activities. It induces apoptosis and is a potent Dengue virus inhibitor with low toxicity. Its low oral bioavailability (~4.4%) makes it a useful negative control for formulation studies. Hirsutine is not an approved drug and is exclusively used as a research tool for cardiovascular, anticancer, and pharmacokinetic studies. |
| Molecular Formula |
C22H28N2O3
|
|---|---|
| Molecular Weight |
368.4693
|
| Exact Mass |
368.209
|
| CAS # |
7729-23-9
|
| PubChem CID |
3037884
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
531.7±50.0 °C at 760 mmHg
|
| Melting Point |
101℃
|
| Flash Point |
275.4±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.613
|
| LogP |
3.96
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
578
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC[C@H]1CN2CCC3=C([C@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=CC=CC=C34
|
| InChi Key |
NMLUOJBSAYAYEM-AZQGJTAVSA-N
|
| InChi Code |
InChI=1S/C22H28N2O3/c1-4-14-12-24-10-9-16-15-7-5-6-8-19(15)23-21(16)20(24)11-17(14)18(13-26-2)22(25)27-3/h5-8,13-14,17,20,23H,4,9-12H2,1-3H3/b18-13+/t14-,17-,20+/m0/s1
|
| Chemical Name |
methyl (E)-2-[(2S,3R,12bR)-3-ethyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~271.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7139 mL | 13.5696 mL | 27.1393 mL | |
| 5 mM | 0.5428 mL | 2.7139 mL | 5.4279 mL | |
| 10 mM | 0.2714 mL | 1.3570 mL | 2.7139 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
